109 related articles for article (PubMed ID: 12546960)
41. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
42. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan.
Iwai T; Yokota S; Nakao M; Okamoto T; Taniwaki M; Onodera N; Watanabe A; Kikuta A; Tanaka A; Asami K; Sekine I; Mugishima H; Nishimura Y; Koizumi S; Horikoshi Y; Mimaya J; Ohta S; Nishikawa K; Iwai A; Shimokawa T; Nakayama M; Kawakami K; Gushiken T; Hyakuna N; Fujimoto T
Leukemia; 1999 Jan; 13(1):38-43. PubMed ID: 10049058
[TBL] [Abstract][Full Text] [Related]
43. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
44. Class III receptor tyrosine kinases: role in leukaemogenesis.
Reilly JT
Br J Haematol; 2002 Mar; 116(4):744-57. PubMed ID: 11886377
[No Abstract] [Full Text] [Related]
45. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.
Murphy KM; Levis M; Hafez MJ; Geiger T; Cooper LC; Smith BD; Small D; Berg KD
J Mol Diagn; 2003 May; 5(2):96-102. PubMed ID: 12707374
[TBL] [Abstract][Full Text] [Related]
46. FLT3/ITD mutation was not detected in a large series of non-Hodgkin lymphomas.
Shiozawa E; Takimoto M; Adachi D; Ota H
Leuk Res; 2004 Sep; 28(9):997-8. PubMed ID: 15234579
[No Abstract] [Full Text] [Related]
47. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
48. The role of FLT3 in haematopoietic malignancies.
Stirewalt DL; Radich JP
Nat Rev Cancer; 2003 Sep; 3(9):650-65. PubMed ID: 12951584
[TBL] [Abstract][Full Text] [Related]
49. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
[TBL] [Abstract][Full Text] [Related]
50. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
51. Flt3/Itd mutation is not associated with gastrointestinal stromal tumors (gists).
Shiozawa E; Takimoto M; Makino R; Hirayama Y; Ota H
J Gastroenterol Hepatol; 2005 Jul; 20(7):1132-4. PubMed ID: 15955231
[No Abstract] [Full Text] [Related]
52. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
Yanada M; Matsuo K; Suzuki T; Kiyoi H; Naoe T
Leukemia; 2005 Aug; 19(8):1345-9. PubMed ID: 15959528
[TBL] [Abstract][Full Text] [Related]
54. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Stone RM; De Angelo J; Galinsky I; Estey E; Klimek V; Grandin W; Lebwohl D; Yap A; Cohen P; Fox E; Neuberg D; Clark J; Gilliland DG; Griffin JD
Ann Hematol; 2004; 83 Suppl 1():S89-90. PubMed ID: 15124689
[No Abstract] [Full Text] [Related]
55. Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.
Scholl S; Loncarevic IF; Krause C; Kunert C; Clement JH; Höffken K
Leuk Res; 2005 Jul; 29(7):849-53. PubMed ID: 15921740
[TBL] [Abstract][Full Text] [Related]
56. FLT3 mutations are associated with other molecular lesions in AML.
Carnicer MJ; Nomdedéu JF; Lasa A; Estivill C; Brunet S; Aventín A; Sierra J
Leuk Res; 2004 Jan; 28(1):19-23. PubMed ID: 14630076
[TBL] [Abstract][Full Text] [Related]
57. Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis.
Abu-Duhier FM; Goodeve AC; Care RS; Gari M; Wilson GA; Peake IR; Reilly JT
Br J Haematol; 2003 Feb; 120(3):464-70. PubMed ID: 12580961
[TBL] [Abstract][Full Text] [Related]
58. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
59. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines.
Yokota S; Kiyoi H; Nakao M; Iwai T; Misawa S; Okuda T; Sonoda Y; Abe T; Kahsima K; Matsuo Y; Naoe T
Leukemia; 1997 Oct; 11(10):1605-9. PubMed ID: 9324277
[TBL] [Abstract][Full Text] [Related]
60. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
Christiansen DH; Pedersen-Bjergaard J
Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
